See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

  • All
  • AAN
  • ESPID
  • APCCMI
  • ASCP
  • ASM Microbe
  • AVG and IMRP
  • CROI
  • ESCMID
  • GSA
  • IAS
  • IDWeek
  • ISIRV
  • NACFC
  • SCCM
  • All
  • 2024
  • 2025
  • 2026
  • All
  • Amyotrophic Lateral Sclerosis (ALS)
  • COVID-19
  • Gram-negative infection
  • Respiratory Syncytial Virus (RSV)
  • All
  • Cefiderocol
  • Edaravone
  • Ensitrelvir
  • S-337395
  • S-892216
  • Xeruborbactam
  • All
  • Oral presentation
  • Poster presentation

You Are Viewing Presentations

ESCMID 2026
Cefiderocol

Activity of cefiderocol against Stenotrophomonas maltophilia clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014–2019) and SENTRY (2020–2024)

View/Download Presentation
IDWeek 2025
Cefiderocol

Activity of cefiderocol and comparator agents against carbapenem-resistant Enterobacterales, including molecularly characterized isolates recovered from United States hospitals in 2020–2024

View/Download Presentation
ESCMID 2026
Cefiderocol

Activity of cefiderocol and comparator agents against European enterobacterales, including carbapenem-resistant isolates, from the SENTRY antimicrobial surveillance program (2020–2024)

View/Download Presentation
IDWeek 2024
Cefiderocol

Activity of cefiderocol and comparator agents against global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)

View/Download Presentation
IDWeek 2025
Cefiderocol

Activity of cefiderocol and comparator agents against metallo-β-lactamase carrying Acinetobacter baumannii-calcoaceticus complex isolates collected in the SENTRY antimicrobial surveillance program

View/Download Presentation
IDWeek 2024
Ensitrelvir

Analysis of post COVID-19 condition after ensitrelvir treatment in asymptomatic or mild-symptoms only patients in the SCORPIO phase2b/3 Study

View/Download Presentation

You Are Viewing Congress Locations